Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 6 | 2024 | 577 | 2.940 |
Why?
|
| Brazil | 22 | 2025 | 89 | 1.860 |
Why?
|
| Health Services Accessibility | 9 | 2024 | 546 | 1.630 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 272 | 1.550 |
Why?
|
| Antihypertensive Agents | 4 | 2019 | 173 | 1.250 |
Why?
|
| Health Expenditures | 3 | 2020 | 118 | 1.100 |
Why?
|
| Cost Sharing | 4 | 2020 | 14 | 1.020 |
Why?
|
| Diabetes Mellitus | 6 | 2022 | 538 | 1.000 |
Why?
|
| Socioeconomic Factors | 4 | 2024 | 792 | 0.900 |
Why?
|
| Pharmaceutical Services | 3 | 2018 | 32 | 0.800 |
Why?
|
| Interrupted Time Series Analysis | 6 | 2022 | 28 | 0.740 |
Why?
|
| Hypoglycemic Agents | 3 | 2019 | 211 | 0.720 |
Why?
|
| Drug Costs | 3 | 2017 | 59 | 0.710 |
Why?
|
| Health Policy | 4 | 2019 | 183 | 0.710 |
Why?
|
| Commerce | 2 | 2019 | 59 | 0.700 |
Why?
|
| Hypertension | 4 | 2020 | 603 | 0.670 |
Why?
|
| Financing, Government | 1 | 2020 | 33 | 0.670 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1481 | 0.660 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 100 | 0.660 |
Why?
|
| Smoking | 1 | 2024 | 835 | 0.640 |
Why?
|
| Retrospective Studies | 13 | 2025 | 6139 | 0.630 |
Why?
|
| Pharmaceutical Preparations | 3 | 2015 | 122 | 0.620 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2017 | 26 | 0.570 |
Why?
|
| Drug Industry | 1 | 2017 | 40 | 0.560 |
Why?
|
| Insurance, Health | 1 | 2015 | 143 | 0.460 |
Why?
|
| Education, Continuing | 1 | 2014 | 24 | 0.460 |
Why?
|
| Capacity Building | 1 | 2014 | 22 | 0.460 |
Why?
|
| Education, Distance | 1 | 2014 | 35 | 0.450 |
Why?
|
| Incidence | 4 | 2024 | 1265 | 0.440 |
Why?
|
| Humans | 32 | 2025 | 60132 | 0.440 |
Why?
|
| National Health Programs | 4 | 2019 | 13 | 0.430 |
Why?
|
| Medication Adherence | 1 | 2015 | 254 | 0.430 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 424 | 0.410 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 190 | 0.390 |
Why?
|
| Acute Disease | 1 | 2013 | 661 | 0.380 |
Why?
|
| Female | 15 | 2025 | 31250 | 0.380 |
Why?
|
| Health Personnel | 1 | 2014 | 343 | 0.350 |
Why?
|
| Aged | 9 | 2024 | 13581 | 0.350 |
Why?
|
| Male | 13 | 2025 | 27971 | 0.340 |
Why?
|
| Middle Aged | 12 | 2025 | 16535 | 0.340 |
Why?
|
| Primary Health Care | 2 | 2022 | 660 | 0.340 |
Why?
|
| Malaria | 1 | 2011 | 100 | 0.330 |
Why?
|
| Risk Factors | 5 | 2024 | 5082 | 0.300 |
Why?
|
| Drugs, Essential | 2 | 2018 | 2 | 0.300 |
Why?
|
| Adult | 8 | 2025 | 15985 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2014 | 568 | 0.280 |
Why?
|
| Drugs, Generic | 3 | 2019 | 17 | 0.270 |
Why?
|
| Honduras | 3 | 2015 | 3 | 0.270 |
Why?
|
| Guatemala | 3 | 2015 | 4 | 0.270 |
Why?
|
| Nicaragua | 3 | 2015 | 16 | 0.270 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1237 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 743 | 0.250 |
Why?
|
| Cross-Sectional Studies | 6 | 2018 | 2505 | 0.250 |
Why?
|
| Ivermectin | 1 | 2025 | 11 | 0.240 |
Why?
|
| Prevalence | 3 | 2024 | 1300 | 0.240 |
Why?
|
| Chloroquine | 1 | 2025 | 49 | 0.240 |
Why?
|
| Hydroxychloroquine | 1 | 2025 | 21 | 0.240 |
Why?
|
| Azithromycin | 1 | 2025 | 27 | 0.240 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 33 | 0.220 |
Why?
|
| Sex Distribution | 1 | 2024 | 255 | 0.220 |
Why?
|
| Esophagectomy | 1 | 2024 | 47 | 0.220 |
Why?
|
| Age Distribution | 1 | 2024 | 262 | 0.220 |
Why?
|
| Chronic Disease | 2 | 2018 | 745 | 0.220 |
Why?
|
| Esophageal Neoplasms | 1 | 2024 | 80 | 0.210 |
Why?
|
| Fees, Pharmaceutical | 2 | 2015 | 6 | 0.210 |
Why?
|
| Smokers | 1 | 2023 | 112 | 0.210 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 6 | 0.200 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 5 | 0.200 |
Why?
|
| Robotics | 1 | 2022 | 54 | 0.190 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2023 | 98 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2024 | 268 | 0.180 |
Why?
|
| Thoracic Surgery | 1 | 2022 | 68 | 0.180 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 32 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2022 | 146 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2020 | 34 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 391 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 155 | 0.180 |
Why?
|
| Databases, Factual | 1 | 2024 | 849 | 0.180 |
Why?
|
| Frailty | 1 | 2022 | 126 | 0.180 |
Why?
|
| Program Evaluation | 2 | 2020 | 488 | 0.180 |
Why?
|
| Registries | 1 | 2024 | 809 | 0.180 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 460 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 332 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 1 | 2023 | 172 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 100 | 0.170 |
Why?
|
| Government Programs | 1 | 2020 | 20 | 0.170 |
Why?
|
| Pandemics | 2 | 2025 | 629 | 0.170 |
Why?
|
| Community Pharmacy Services | 1 | 2019 | 14 | 0.170 |
Why?
|
| Robotic Surgical Procedures | 1 | 2022 | 112 | 0.170 |
Why?
|
| Quality Improvement | 1 | 2024 | 428 | 0.160 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 928 | 0.160 |
Why?
|
| Public Health | 1 | 2021 | 180 | 0.160 |
Why?
|
| Mass Screening | 1 | 2024 | 662 | 0.160 |
Why?
|
| Longevity | 1 | 2019 | 112 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2022 | 524 | 0.150 |
Why?
|
| Losartan | 1 | 2017 | 18 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 191 | 0.140 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 22 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 203 | 0.140 |
Why?
|
| Medicare | 1 | 2021 | 603 | 0.140 |
Why?
|
| Lung | 1 | 2021 | 842 | 0.140 |
Why?
|
| Linear Models | 1 | 2017 | 422 | 0.130 |
Why?
|
| Young Adult | 2 | 2024 | 4396 | 0.130 |
Why?
|
| Drug and Narcotic Control | 1 | 2015 | 30 | 0.120 |
Why?
|
| Americas | 1 | 2014 | 5 | 0.120 |
Why?
|
| Professional Competence | 1 | 2014 | 89 | 0.110 |
Why?
|
| Private Sector | 2 | 2010 | 14 | 0.110 |
Why?
|
| Public Sector | 2 | 2010 | 19 | 0.100 |
Why?
|
| Research | 1 | 2014 | 190 | 0.100 |
Why?
|
| Health Care Surveys | 1 | 2013 | 281 | 0.100 |
Why?
|
| Income | 1 | 2013 | 162 | 0.100 |
Why?
|
| United States | 2 | 2024 | 7622 | 0.100 |
Why?
|
| Quality of Life | 1 | 2019 | 1140 | 0.100 |
Why?
|
| Cities | 2 | 2021 | 25 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 969 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2023 | 5197 | 0.090 |
Why?
|
| World Health Organization | 1 | 2009 | 30 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2024 | 1937 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2009 | 331 | 0.070 |
Why?
|
| Outpatients | 1 | 2025 | 140 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2025 | 486 | 0.060 |
Why?
|
| Stomach | 1 | 2024 | 84 | 0.060 |
Why?
|
| Portugal | 1 | 2023 | 2 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2023 | 7 | 0.050 |
Why?
|
| State Medicine | 1 | 2023 | 13 | 0.050 |
Why?
|
| Adolescent | 1 | 2013 | 5958 | 0.050 |
Why?
|
| Morbidity | 1 | 2022 | 110 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 108 | 0.050 |
Why?
|
| Emergencies | 1 | 2022 | 114 | 0.050 |
Why?
|
| Logistic Models | 1 | 2024 | 1259 | 0.040 |
Why?
|
| Health Services | 1 | 2021 | 85 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 61 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 377 | 0.040 |
Why?
|
| Pharmacies | 1 | 2019 | 36 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2022 | 334 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 322 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 164 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 454 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2019 | 210 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2022 | 699 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 2616 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2022 | 1172 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2015 | 43 | 0.030 |
Why?
|
| Suriname | 1 | 2014 | 1 | 0.030 |
Why?
|
| El Salvador | 1 | 2014 | 4 | 0.030 |
Why?
|
| Colombia | 1 | 2014 | 14 | 0.030 |
Why?
|
| Dominican Republic | 1 | 2014 | 23 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2014 | 82 | 0.030 |
Why?
|
| Health Services Research | 1 | 2014 | 270 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2023 | 5262 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 3618 | 0.020 |
Why?
|